Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

192.96 +1.59 (+0.83%)
Streaming Delayed Price Updated: 10:10 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
News headline image
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push ↗
Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam... 
Via MarketBeat
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Via Chartmill
News headline image
Best Healthcare Stocks to Buy in 2026 ↗
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies. 
Via The Motley Fool
Unusual volume S&P500 stocks in Thursday's session ↗
Via Chartmill
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
Discover the top S&P500 movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development 
From Biogen Inc.
Via GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
Via Investor Brand Network
Topics Intellectual Property
News headline image
3 Healthcare Stocks We’re Skeptical Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-... 
Via StockStory
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
3 Value Stocks We Approach with Caution
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings ↗
Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock. 
Via Benzinga
News headline image
Why Biogen Stock Was a Winner on Wednesday ↗
The biotech's growth portfolio continues to add to its overall top line. 
Via The Motley Fool
News headline image
Biogen (BIIB) Q1 2026 Earnings Transcript ↗
Biogen (BIIB) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know. Biogen beat analysts’ revenue ex... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Biogen (BIIB) Q4 2024 Earnings Call Transcript ↗
Biogen (BIIB) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Q3 2024 Earnings Transcript ↗
Biogen (BIIB) Q3 2024 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (BIIB) Q2 2025 Earnings Transcript ↗
Biogen (BIIB) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (BIIB) Q3 2025 Earnings Transcript ↗
Biogen (BIIB) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Economy
News headline image
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen
Check out the companies making headlines yesterday: Cadence Design Systems (NASDAQ:CDNS): Electronic design automation company Cadence Design Systems (NASDAQ... 
Via StockStory
Topics Economy Electric Vehicles
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% ga... 
Via StockStory
Topics Stocks
News headline image
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.6% in the afternoon session after the company received an analyst upgrade from Wells F... 
Via StockStory
Topics World Trade
Top S&P500 movers in Monday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.